L-glutamine combined with chemotherapy produced a 44% response rate in [...]

A $2.5m National Institutes of Health award will support research [...]

The US FDA has approved Revolution Medicines’ daraxonrasib for adults [...]

The FDA has granted Fast Track designation to Erasca’s investigational [...]

Vaximm AG has completed analysis of two clinical studies evaluating [...]

Erasca has reported updated preliminary Phase 1 data for its [...]

Elicio Therapeutics has reported that its Phase 2 Amplify-7P trial [...]

CuraCell TX has reported new findings supporting its personalised tumour-infiltrating [...]

Nature publishes Phase 1b data showing NETRIS Pharma’s NP137 improves [...]

N4 Pharma plc, the UK biotech developing its proprietary Nuvec® [...]